What is the address of Service d'Oncologie Radiothérapie Médecine Nucléaire?

The registered office of Service d'Oncologie Radiothérapie Médecine Nucléaire is located at Chaussée de Dinant(WP) 894, 5100 Namur.

Is Service d'Oncologie Radiothérapie Médecine Nucléaire still active?

Yes. According to the CBE (30 October 2026) Service d'Oncologie Radiothérapie Médecine Nucléaire is active, legal situation “Normale toestand”, started on 12 April 2007.

Is Service d'Oncologie Radiothérapie Médecine Nucléaire registered on Peppol?

Yes, Service d'Oncologie Radiothérapie Médecine Nucléaire is registered on the Peppol network with ID 0208:0888714988.

Who are the directors of Service d'Oncologie Radiothérapie Médecine Nucléaire?

According to the 2025 annual accounts, the directors of Service d'Oncologie Radiothérapie Médecine Nucléaire are: BEVERGAM SRL, DOCTEUR GABRIËL SRL, VANHAUDENARDE ONCOLOGIE SRL.

Is Service d'Oncologie Radiothérapie Médecine Nucléaire a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 April 2007; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

What is the revenue of Service d'Oncologie Radiothérapie Médecine Nucléaire?

As a small company, Service d'Oncologie Radiothérapie Médecine Nucléaire is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 13,575.

Service d'Oncologie Radiothérapie Médecine Nucléaire

Q: What does Service d'Oncologie Radiothérapie Médecine Nucléaire do?

Service d'Oncologie Radiothérapie Médecine Nucléaire is a healthcare practice in Namur. Cooperative, started on 12 April 2007, 1 establishment.

Q: What is the enterprise number of Service d'Oncologie Radiothérapie Médecine Nucléaire?

The enterprise number of Service d'Oncologie Radiothérapie Médecine Nucléaire is BE0888714988.

Q: When was Service d'Oncologie Radiothérapie Médecine Nucléaire founded?

Service d'Oncologie Radiothérapie Médecine Nucléaire was founded on 12 April 2007.

Q: How much profit did Service d'Oncologie Radiothérapie Médecine Nucléaire make in 2025?

Service d'Oncologie Radiothérapie Médecine Nucléaire posted a profit after taxes of € 0 in financial year 2025.

Dossier Service d'Oncologie Radiothérapie Médecine Nucléaire, printed on 30 October 2026 from databakkes.be/en/0888714988/service-d-oncologie-radiotherapie-medecine-nucleaire. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Service d'Oncologie Radiothérapie Médecine Nucléaire from Namur, company number BE0888714988, closed financial year 2025 with a result of € 0 after tax. For that financial year Service d'Oncologie Radiothérapie Médecine Nucléaire recorded a gross margin of € 13,575 and equity of € 40,643. Compared with financial year 2024, the result moved from € -5 to € 0. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.

What it is worth Growing

€ 40,643

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 0

▲ still € 5 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.3 million

▲ 95% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 3,432.

People and assets in 2025

Vehicles and equipment

€ 1,500

▼ 50% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3.3 million

▲ 12% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 21,715

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 16,687 Gross margin 2022: € 16,687 First fiscal year in the series	€ 14,552 Gross margin 2023: € 14,552 ▼ 13% vs 2022 (€ 16,687) Unfavourable step	€ 13,049 Gross margin 2024: € 13,049 ▼ 10% vs 2023 (€ 14,552) Unfavourable step	€ 13,575 Gross margin 2025: € 13,575 ▲ 4% vs 2024 (€ 13,049) Favourable step	▲ 4%
Profit after taxes	€ -7 Profit after taxes 2022: € -7 First fiscal year in the series	€ 3 Profit after taxes 2023: € 3 ▲ € 10 vs 2022 (€ -7) Favourable step	€ -5 Profit after taxes 2024: € -5 ▼ € 8 vs 2023 (€ 3) Unfavourable step	€ 0 Profit after taxes 2025: € 0 ▲ € 5 vs 2024 (€ -5) Favourable step	▲ € 5
Equity	€ 33,926 Equity 2022: € 33,926 First fiscal year in the series	€ 37,512 Equity 2023: € 37,512 ▲ 11% vs 2022 (€ 33,926) Favourable step	€ 37,955 Equity 2024: € 37,955 ▲ 1% vs 2023 (€ 37,512) Favourable step	€ 40,643 Equity 2025: € 40,643 ▲ 7% vs 2024 (€ 37,955) Favourable step	▲ 7%
Total debts	€ 1,108,573 Total debts 2022: € 1,108,573 First fiscal year in the series	€ 1,567,096 Total debts 2023: € 1,567,096 ▲ 41% vs 2022 (€ 1,108,573) Unfavourable step	€ 2,928,563 Total debts 2024: € 2,928,563 ▲ 87% vs 2023 (€ 1,567,096) Unfavourable step	€ 3,295,437 Total debts 2025: € 3,295,437 ▲ 13% vs 2024 (€ 2,928,563) Unfavourable step	▲ 13%
Cash	€ 54,541 Cash 2022: € 54,541 First fiscal year in the series	€ 70,295 Cash 2023: € 70,295 ▲ 29% vs 2022 (€ 54,541) Favourable step	€ 653,368 Cash 2024: € 653,368 ▲ € 583,073 vs 2023 (€ 70,295) Favourable step	€ 1,275,566 Cash 2025: € 1,275,566 ▲ 95% vs 2024 (€ 653,368) Favourable step	▲ 95%
Retained profit	€ 3,433 Retained profit 2022: € 3,433 First fiscal year in the series	€ 3,436 Retained profit 2023: € 3,436 Unchanged (€ 3,433) Favourable step	€ 3,431 Retained profit 2024: € 3,431 Unchanged (€ 3,436) Unfavourable step	€ 3,432 Retained profit 2025: € 3,432 Unchanged (€ 3,431) Favourable step
Balance sheet total	€ 1,142,498 Balance sheet total 2022: € 1,142,498 First fiscal year in the series	€ 1,604,608 Balance sheet total 2023: € 1,604,608 ▲ 40% vs 2022 (€ 1,142,498) Unchanged	€ 2,966,518 Balance sheet total 2024: € 2,966,518 ▲ 85% vs 2023 (€ 1,604,608) Unchanged	€ 3,336,079 Balance sheet total 2025: € 3,336,079 ▲ 12% vs 2024 (€ 2,966,518) Unchanged	▲ 12%

Key figures of Service d'Oncologie Radiothérapie Médecine Nucléaire, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Service d'Oncologie Radiothérapie Médecine Nucléaire?

What happened at Service d'Oncologie Radiothérapie Médecine Nucléaire in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 BEVERGAM SRL stepped down as director. NBB
2029 DOCTEUR GABRIËL SRL stepped down as director. NBB
2029 VANHAUDENARDE ONCOLOGIE SRL stepped down as director. NBB
May 28, 2026 New annual accounts for financial year 2025: profit of € 0. Source: NBB ↗
2024 BEVERGAM SRL became a director. NBB
2024 DOCTEUR GABRIËL SRL became a director. NBB
2024 VANHAUDENARDE ONCOLOGIE SRL became a director. NBB
Apr 12, 2007 New establishment in Namur. KBO

In short

From € 7 loss in 2022 to € 0 profit in 2025.

Paid € 45,864 in corporate taxes since 2022.

Best year ever: 2023, with € 3 profit.

Original PDFs at the National Bank ↗

Management

NUCLEARIS I.M. 5.5%

CABINET MEDICAL MOSE 5.5%

BEVERGAM 5.3%

JC GOEMINNE 4.7%

The stake of NUCLEARIS I.M., CABINET MEDICAL MOSE, BEVERGAM, JC GOEMINNE, CABINET MEDICAL HENRIET-MOURIN, Stéphanie Deheneffe Radiothérapie comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Service d'Oncologie Radiothérapie Médecine Nucléaire

The shares are held by NUCLEARIS I.M. (5.5%), CABINET MEDICAL MOSE (5.5%), BEVERGAM (5.3%), JC GOEMINNE (4.7%), CABINET MEDICAL HENRIET-MOURIN (4.4%) and Stéphanie Deheneffe Radiothérapie (0.1%).

Directors

According to the 2025 annual accounts

BEVERGAM SRL

Managing director · represented by Bernard WILLEMART

since 2024 · until 2029

DOCTEUR GABRIËL SRL

Director · represented by Stéphanie GABRIËL

since 2024 · until 2029

VANHAUDENARDE ONCOLOGIE SRL

Director · represented by Vincent VANHAUDENARDE

since 2024 · until 2029

Shareholders

5.5%

5.5%

5.3%

4.7%

CABINET MEDICAL HENRIET-MOURIN

4.4%

Stéphanie Deheneffe Radiothérapie

0.1%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Dinant(WP) 894

5100 Namur

2.229.107.609

Place Louise Godin 15

5000 Namur

Active since 12 April 2007

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

BEVERGAM same network

€ 315,049 gross margin · 2025

FINAWEP

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0888.714.988

VAT number

BE 0888.714.988

Registered office

Chaussée de Dinant(WP) 894, 5100 Namur

Names & denominations

Service d'Oncologie Radiothérapie Médecine Nucléaire

Enterprise type

Rechtspersoon

Legal form

Cooperative company

Legal situation

Normale toestand

Start date

12 April 2007

Peppol

Active · Active since 23 Jan 2026

Activities · NACE

Activiteiten van medische beeldvorming en medische laboratoria

Activiteiten van medische laboratoria

View on CBE Public ↗ Annual accounts (NBB) ↗

Service d'Oncologie Radiothérapie Médecine Nucléaire

Financials

What happened to Service d'Oncologie Radiothérapie Médecine Nucléaire?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions